Literature DB >> 14673773

Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters.

Michelle M Merrigan1, Susan P Sambol, Stuart Johnson, Dale N Gerding.   

Abstract

Clostridium difficile-associated disease (CDAD) due to toxigenic strains is prevented in hamsters by colonization by nontoxigenic C. difficile after administration of clindamycin (Cm). To prevent CDAD during treatment with antibiotics, we gave a Cm-resistant nontoxigenic C. difficile strain, M13 (minimal inhibitory concentration [MIC], >256 microg/mL), and a Cm-susceptible strain, M3 (MIC, 0.5 microg/mL), to hamsters receiving Cm daily for days 1-5. Either M13 or M3 was given orogastrically (1 x 10(6) spores/day) to each hamster in 3 groups of 5 each, on either day 3, days 3-5, or days 3-7. M13 colonized at a higher rate and faster than did M3 (P<.001). When hamsters were challenged by toxigenic strain B1 on days 5, 7, or 9, M13 prevented CDAD in 100% of the hamsters. M3 protected no hamsters challenged by B1 on day 5, 20% on day 7, and 100% on day 9. M13 contains the erm(B) resistance gene but not the mobilizable element Tn5398. The benefits of use of Cm-resistant nontoxigenic C. difficile to prevent CDAD must be balanced against the risk that resistance might be transferred to other enteric bacteria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14673773     DOI: 10.1086/379836

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

Review 1.  Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance.

Authors:  Robert A Britton; Vincent B Young
Journal:  Trends Microbiol       Date:  2012-05-15       Impact factor: 17.079

2.  Gender Differences in Non-Toxigenic Clostridium difficile Colonization and Risk of Subsequent C. difficile Infection.

Authors:  Mukil Natarajan; Mary Am Rogers; Jacob Bundy; Dejan Micic; Seth T Walk; Kavitha Santhosh; Krishna Rao; Spencer Winters; Vincent B Young; David M Aronoff
Journal:  Clin Res Infect Dis       Date:  2015-08-03

3.  In vitro killing of nosocomial pathogens by acid and acidified nitrite.

Authors:  Agam Rao; Robin L P Jump; Nicole J Pultz; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

4.  [Clostridium difficile infection : What is currently available for treatment?]

Authors:  A Stallmach
Journal:  Internist (Berl)       Date:  2016-12       Impact factor: 0.743

Review 5.  Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-10       Impact factor: 46.802

6.  The correlation between Clostridium-difficile infection and human gut concentrations of Bacteroidetes phylum and clostridial species.

Authors:  E Goldberg; I Amir; M Zafran; U Gophna; Z Samra; S Pitlik; J Bishara
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-19       Impact factor: 3.267

7.  Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1.

Authors:  David Goulding; Harold Thompson; Jenny Emerson; Neil F Fairweather; Gordon Dougan; Gill R Douce
Journal:  Infect Immun       Date:  2009-09-14       Impact factor: 3.441

8.  Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea?

Authors:  Robin L P Jump; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

Review 9.  Clostridium difficile Infection.

Authors:  Jae Hyun Shin; Esteban Chaves-Olarte; Cirle A Warren
Journal:  Microbiol Spectr       Date:  2016-06

Review 10.  A clinical and epidemiological review of non-toxigenic Clostridium difficile.

Authors:  Mukil Natarajan; Seth T Walk; Vincent B Young; David M Aronoff
Journal:  Anaerobe       Date:  2013-05-29       Impact factor: 3.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.